Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose
Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and
clinical activity.